Rocket Pharmaceuticals, Inc. — Operating Income by Fiscal Year
12 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/59d3ebbd-3ead-491f-bfa5-408642346f35/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-231.7M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-076551 |
| FY 2024 | $-273.2M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-029002 |
| FY 2023 | $-259.7M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-021096 |
| FY 2022 | $-224.3M | 2022-01-01 – 2022-12-31 | evidence 0001140361-23-009252 |
| FY 2021 | $-167.2M | 2021-01-01 – 2021-12-31 | evidence 0001140361-22-007036 |
| FY 2020 | $-134.3M | 2020-01-01 – 2020-12-31 | evidence 0001140361-21-006677 |
| FY 2019 | $-76.2M | 2019-01-01 – 2019-12-31 | evidence 0001140361-20-005056 |
| FY 2018 | $-71.2M | 2018-01-01 – 2018-12-31 | evidence 0001140361-19-004603 |
| FY 2017 | $-19.8M | 2017-01-01 – 2017-12-31 | evidence 0001140361-19-004603 |
| FY 2016 | $-7.6M | 2016-01-01 – 2016-12-31 | evidence 0001140361-19-004603 |
| FY 2015 | $-20.4M | 2015-01-01 – 2015-12-31 | evidence 0001193125-16-514228 |
| FY 2014 | $-7.7M | 2014-01-01 – 2014-12-31 | evidence 0001193125-16-514228 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Rocket Pharmaceuticals, Inc. — all facts · Revenue · Net Income